Managing Recurrent SCCHN in the Era of Immunotherapy: Opportunities and Hurdles in Daily Clinical Practice
Release date: 24-06-2021
Expiration date: 24-06-2022
The management of recurrent/metastatic (R/M) squamous cell cancer of the head and neck (SCCHN) is evolving rapidly, and physicians often face clinical situations in which selecting the optimal treatment for individual patients is challenging. View expert faculty presentations, panel discussions, and downloadable slides from this live webinar, and gain insights on managing difficult clinical situations and on the most promising novel strategies in clinical trials.
Ye Guo, MD | Chair
Department of Medical Oncology
Shanghai East Hospital Tongji
University School of Medicine
Ye Guo, MD, is the Deputy Director of the Oncology Department at Tongji University East Hospital in Shanghai, China. His research focuses on new drug development, and he serves as Director of the Phase I Trial Unit at Tongji University, Shanghai East Hospital. Previously, Dr. Guo led the research team for head and neck (H&N) cancer and lymphoma at Fudan University Shanghai Cancer Center where he has been Deputy Director of the Medical Oncology Department since 2010. He is the Deputy Secretary-General of the Chinese Society of Clinical Oncology (CSCO), Chairman of the H&N Cancer Committee (CSCO), member of the Standing Committee of the Union of Chinese Lymphoma Investigators (UCLI), Vice Chairman of the H&N Cancer Committee and Secretary-General of the Lymphoma Committee of Shanghai Anti-Cancer Association. Dr. Guo is a principal investigator for multiple key clinical trials of H&N cancer in China, and has published numerous articles in international, peer-reviewed journals, and is the Chair of the CSCO Guidelines for H&N cancer.
Joël Guigay, MD, PhD
Cancer Center Antoine-Lacassagne
Université Côte d’Azur
Joël Guigay is Professor of Medicine and Past-Director of the Cancer Center Antoine-Lacassagne in Nice, France. Previously, he was Head Physician in the Department of Head & Neck and Thoracic Medical Oncology at Gustave Roussy in Villejuif, France. Professor Guigay received his medical degree from Lyon University of Medicine in 1984 and, subsequently, undertook extensive postgraduate training in pneumology, cancerology, oncogenesis, and thoracic endoscopy. In 2001, he was appointed Professor of Medicine at the Hôpital d’Instruction des Armées Val-de-Grâce in Paris, France. He currently serves as the President of the Head & Neck Unicancer group, and as Deputy Director of the Hospital University Federative OncoAge. Professor Guigay is an active member of many national and international societies, including the American Society of Clinical Oncology (ASCO), the European Society for Medical Oncology (ESMO) as a Faculty member for Head and Neck cancers and as a member of the OncologyPro WG, the Head and Neck Cancer International Group (HNCIG) as Co-Chair of the scientific committee, the Groupe Oncologie Radiothérapie Tête et Cou (GORTEC) as a member of the board and the scientific committee, the International Association for the Study of Lung Cancer (IASLC), and the Intergroupe Francophone de Cancérologie Thoracique (IFCT). His main fields of interest are head and neck, and lung, oncology with a focus on rare tumors, salivary gland tumors, nasopharyngeal cancers, and neuroendocrine tumors. His areas of research include clinical studies with new drugs and translational research, with a focus on immunotherapy. Professor Guigay coordinates several clinical trials including phase I to large randomized trials in recurrent or metastatic HNSCC, such as the TPExtreme trial. He also currently leads a large research program for elderly head and neck cancer patients (ELAN study).
Guopei Zhu, MD
The Shanghai Ninth People’s Hospital
Shanghai Jiaotong University School of Medicine
Guopei Zhu is the Chief Physician of Shanghai Ninth People’s Hospital, Shanghai Jiaotong University, School of Medicine, Shanghai, China, and is the Director of Radiation Oncology Division in the Department of Oral and Maxillofacial-Head and Neck Oncology. Professor Zhu is Vice Chairman of the Head and Neck Cancer Professional Committee, and the Nasopharyngeal Carcinoma Professional Committee, of the Shanghai Anti-Cancer Association. Professor Zhu is a member of the Head and Neck Cancer Professional Committee of the Chinese Society of Clinical Oncology (CSCO), member of the Nasopharyngeal Carcinoma Professional Committee of CSCO and a member of the Standing Committee of the Oral and Maxillofacial Head and Neck Cancer Professional Committee of the Chinese Stomatological Association.
- Managing R/M SCCHN in the era of immunotherapy: Where does anti-EGFR-based therapy fit? | Joël Guigay, MD, PhD
- How I treat: Challenging clinical scenarios in R/M SCCHN | Guopei Zhu, MD
- R/M SCCHN: Looking to the future | Ye Guo, MD
This meeting is designed specifically for medical oncologists, radiation oncologists, and other members of the head and neck multidisciplinary team involved in the treatment of patients with head and neck cancer.
Upon completion of this educational activity, participants should be able to:
- Evaluate the role of anti-EGFR based therapy in R/M SCCHN in the era of immunotherapy based on the latest data and guideline recommendations
- Select the optimal treatment approach first-line and beyond for patients with R/M SCCHN considering patient and disease characteristics, evidence-based data and treatment availability
- Describe ongoing immunotherapeutic strategies in clinical trials to enhance activity of immune checkpoint inhibition
Provided by ACE Oncology.
This educational activity is supported by an independent grant from the Healthcare business of Merck KGaA, Darmstadt, Germany.
This activity provides content that is evidence-based, balanced, and free of commercial bias, with a primary objective to improve competence and performance of learners in order to improve patient care.
The faculty reported the following financial relationships or relationships to products or devices they or their spouses/life partners have with commercial interest related to the content of this activity:
Ye Guo has served as an advisor or consultant for Merck Serono, Boehringer Ingelheim, BMS, and MSD. He has served as a speaker or a member of a speakers bureau for Merck Serono, Roche, Celgene, Janssen, Bayer, BMS, and MSD. Any unlabeled/unapproved uses of drugs or products referenced in his presentation will be specified.
Joel Guigay has served as an advisor or consultant for Merck Serono, BMS, AstraZeneca, Innate Pharma, and Roche. He has served as a speaker for MSD. His institution has received grants for clinical research from Merck Serono and BMS. Any labeled/unapproved uses of drugs and products referenced in his presentation will be specified.
Guopei Zhu has received grants for clinical research from Jiangsu Hengrui Medicine Co., Ltd, Clinical Research Program of 9th People’s Hospital, and the Shanghai Jiao Tong University School of Medicine. Any unlabeled/unapproved uses of drugs or products referenced in his presentation will be specified.
The employees of ACE Oncology have disclosed no relevant financial relationships.
ACE Oncology require instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COIs are thoroughly vetted and resolved according to ACE Oncology’s policy. ACE Oncology is committed to providing its learners with high-quality activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial entity.